Pages
Products
CAG-Luc AAV (Serotype AAV-BI30)

CAG-Luc AAV (Serotype AAV-BI30)

Cat.No. :  AAV00543Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype AAV-BI30 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00543Z
Description AAV serotype BI30 particles express luciferase reporter gene under the control of CAG promoter for CNS endothelial cell specific expression.
Reporter Luc
Serotype AAV Serotype AAV-BI30
Target Gene Luc
Application

1. Determination of optimal MOI (multiplicity of infection), administration methods etc.

2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue.

3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery.

Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Publications

Q & A

Customer Reviews

Recombinant adeno-associated viral vectors (rAAV) are the leading platform for gene therapy, with four approved products by the end of 2022. rAAV has many advantages as a gene delivery vector, including the ability to transduce a variety of proliferating and non-proliferating cells, adaptability to cell/tissue-specific promoters, and lower immune response induction compared to other viral vectors. Adeno-associated virus (AAV) is a small, non-enveloped virus belonging to the genus Dependovirus in the family Parvoviridae. The 4.6 kb single-stranded DNA genome of AAV contains two viral genes: rep and cap. These genes can be replaced with a gene cassette that expresses a therapeutic transgene while providing the necessary rep and cap genes in trans. The AAV capsid is icosahedral and is assembled from 60 viral protein (VP) monomers, of which there are approximately 5 copies of VP1, 5 copies of VP2, and 50 copies of VP3. Currently, there are several cell culture expression platforms used to produce recombinant adeno-associated virus (rAAV): viral helper platforms, which involve infection of Spodoptera frugiperda (Sf9) insect cells with live baculovirus expression vectors (BEVs) and infection of mammalian cells with adenovirus; stable packaging cell lines that express the rep and cap genes of the desired rAAV serotype; stable proviral production cell lines that stably express rep, cap, and the transgene; and triple plasmid transient transfection (TTT). The triple transient transfection platform is the most common method for producing recombinant adeno-associated virus (rAAV) and uses three plasmids: one plasmid encoding the gene of interest (GOI) flanked by AAV inverted terminal repeats (ITRs); one plasmid encoding the rep and cap genes of AAV; and a third plasmid encoding adenoviral helper function genes. The BEV/Sf9 system is the second most common AAV production platform and offers several advantages, including ease of scale-up and reduced encapsidation of contaminating DNA when producing rAAV. A recent study reported that rAAV capsids produced in HEK293 cells using TTT or BEV/Sf9 cells have different post-translational modifications (PTMs), such as glycosylation, phosphorylation, methylation, and acetylation. In addition, rAAV produced in HEK293 cells using TTT showed better in vitro potency than BEV/Sf9 vectors in various cell types and mouse tissues.
Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Versatile Applications

Using the CAG-Luc AAV (Serotype AAV-BI30) from Creative Biogene has significantly advanced our research on targeted gene therapy. The precise expression patterns we observed were exactly what we needed.

United Kingdom

01/05/2023

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction